Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
|Articles|August 15, 2002
- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Throughput Analysis and Debottlenecking of Biomanufacturing Facilities ? A Job for Process Simulators
by Demetri Petrides, Alexandros Koulouris, and Charles Siletti, Intelligen, Inc. Bottlenecks are everywhere, from the freeway overpass during the morning commute to the long lines at the supermarket. But bottlenecks in a manufacturing process are bad for business. Computer models can help you eliminate those conditions or situations that retard your progress. Whether the goal is strategic planning, evaluating alternatives, purchasing equipment, appraising a facility, or optimizing production processes, simulation tools can improve your analysis.
Advertisement
Articles in this issue
about 24 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesabout 24 years ago
Inside Washington: User Fee Program Seeks to Spur Biotech Developmentabout 24 years ago
Analytical Advances: Mapping Proteins – the 2-D Electrophoresis Issueabout 24 years ago
Your Vested Interests: Gorillas In Our MidstAdvertisement
Related to this article
In an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 440 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.
As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.
All 9 patients treated with BB-301 gene therapy met formal response criteria for improved swallowing in an ongoing OPMD trial.
Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team cuts monoclonal antibody costs without cutting purification steps, and why the $10-per-gram target could make antibodies viable for infectious disease and global access.
Advertisement
Advertisement
Trending on BioPharm International
1
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
2
Leads Biolabs Doses First Lupus Patient With LBL-047, a BDCA2/TACI Bifunctional Fusion Protein
3
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
4
BioMarin Licenses Subcutaneous Fabry ERT From GC Biopharma, Hanmi
5